Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Eileen S. Carpenter

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6775-6943; OpenAlex author ID A5017197654. Sources: OpenAlex.

Their work

Papers
24 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
78
Papers, trials and grants by year

2020: 2 papers · 2021: 6 papers · 2022: 2 papers · 2023: 3 papers · 2024: 4 papers · 2025: 2 papers · 2026: 5 papers

Papers 24

  1. Wilms Tumor 1-Expressing Stromal Cells Promote Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-25-1014↗
  2. Longitudinal Analysis of Matched Patient Biospecimens Reveals Neural Reprogramming of Cancer-Associated Fibroblasts Following Chemotherapy in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-26-0823↗
  3. Aryl Hydrocarbon Receptor Ligands Drive Pancreatic Cancer Initiation and Progression through Protumorigenic T-cell Polarization. Co-author DOI 10.1158/2159-8290.cd-25-0377↗
  4. Asynchronous Evolution of Epithelium and Stroma Differentiates Precursor Lesions from Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-25-2001↗
  5. Targeting CCR1 Remodels the Tumor Microenvironment and Relieves Immunosuppression in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-25-1300↗
  6. Primary and metastatic cellular landscapes in human pancreatic cancer. Co-author DOI 10.1016/j.isci.2025.113012↗
  7. Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-24-0210↗
  8. Pancreatic Cancer-Associated Fibroblasts: Where Do We Go from Here? Co-author DOI 10.1158/0008-5472.can-24-2860↗
  9. KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment. Co-author DOI 10.1158/1078-0432.ccr-23-1421↗
  10. Notch Signaling Regulates Immunosuppressive Tumor-Associated Macrophage Function in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-23-0037↗
  11. Endoscopic Ultrasound-Guided Ablation of Premalignant Pancreatic Cysts and Pancreatic Cancer. Co-author DOI 10.3390/diagnostics14050564↗
  12. Uridine-derived ribose fuels glucose-restricted pancreatic cancer. Co-author DOI 10.1038/s41586-023-06073-w↗
  13. WNT signaling in the tumor microenvironment promotes immunosuppression in murine pancreatic cancer. Co-author DOI 10.1084/jem.20220503↗
  14. Arginase 1 is a key driver of immune suppression in pancreatic cancer. Co-author DOI 10.7554/elife.80721↗
  15. Hypoxia promotes an inflammatory phenotype of fibroblasts in pancreatic cancer. Co-author DOI 10.1038/s41389-022-00434-2↗
  16. Using Single Cell Transcriptomics to Elucidate the Myeloid Compartment in Pancreatic Cancer. Last author DOI 10.3389/fonc.2022.881871↗
  17. Immunotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.26312↗
  18. GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis. Co-author DOI 10.1038/s41467-021-24859-2↗
  19. Nutrient profiling reveals extracellular uridine as a fuel for pancreatic cancer through uridine phosphorylase 1 Co-author DOI 10.1101/2021.06.07.447448↗
  20. Apolipoprotein E Promotes Immune Suppression in Pancreatic Cancer through NF-κB-Mediated Production of CXCL1. First author DOI 10.1158/0008-5472.can-20-3929↗
  21. Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3715↗
  22. Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages. Co-author DOI 10.26508/lsa.202000935↗
  23. Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer. First author DOI 10.1038/s43018-020-00121-4↗
  24. Targeting the Microenvironment to Overcome Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-1692↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marina Pasca di Magliano · 21 shared papers, 2020–2026 · strength 3.26
  2. Filip Bednar · 13 shared papers, 2020–2026 · strength 2.10
  3. Timothy L. Frankel · 11 shared papers, 2020–2026 · strength 1.79
  4. Padma Kadiyala · 9 shared papers, 2022–2026 · strength 1.73
  5. Katelyn L. Donahue · 11 shared papers, 2020–2026 · strength 1.65
  6. Costas Andreas Lyssiotis · 11 shared papers, 2020–2026 · strength 1.43
  7. Ahmed M. Elhossiny · 7 shared papers, 2022–2026 · strength 1.42
  8. Yaqing Zhang · 6 shared papers, 2023–2026 · strength 1.21
  9. Jiaqi Shi · 6 shared papers, 2023–2026 · strength 1.10
  10. Zeribe C. Nwosu · 9 shared papers, 2021–2026 · strength 1.07
  11. Nina G. Steele · 8 shared papers, 2020–2025 · strength 1.04
  12. Vaibhav Sahai · 7 shared papers, 2020–2026 · strength 1.02
  13. Rosa Elena Menjivar · 7 shared papers, 2021–2026 · strength 1.02
  14. Howard C. Crawford · 8 shared papers, 2020–2025 · strength 0.92
  15. Samantha B. Kemp · 7 shared papers, 2020–2025 · strength 0.85
  16. Jorge D. Machicado · 3 shared papers, 2024–2026 · strength 0.65
  17. Emily L. Lasse Opsahl · 3 shared papers, 2025–2026 · strength 0.62
  18. Wenting Du · 4 shared papers, 2023–2024 · strength 0.61
  19. Wei Yan · 3 shared papers, 2024–2026 · strength 0.61
  20. Christopher J. Halbrook · 5 shared papers, 2021–2023 · strength 0.55
  21. Valerie Gunchick · 4 shared papers, 2020–2025 · strength 0.49
  22. Anirban Maitra · 2 shared papers, 2024–2026 · strength 0.44
  23. Brian D. Griffith · 2 shared papers, 2026 · strength 0.43
  24. Yaqing Zhang · 4 shared papers, 2021–2023 · strength 0.42
  25. Allison Bischoff · 2 shared papers, 2023–2026 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.